賽微電子(300456.SZ):北京FAB3正積極推動各類不同的MEMS晶圓進入量產階段
格隆匯5月31日丨有投資者在投資者互動平台向賽微電子(300456.SZ)提問,“北京線濾波器量產如何了?客户是否有實質性下單?貴司的濾波器何時能問世?又是PPT濾波器? 北京線的激光微鏡何時會有訂單?已經過去大半年了,難道又只停留PPT振鏡,在等一段時間下一代都已經出來了?請不不要籠統回覆,謝謝!最後一個問題,懷柔線和光明線還在討論嗎,一個討論就是大半年,萬一能簽署協議,等大半年乃至一年又像合肥項目,德國項目那樣那樣暫緩嗎和取消嗎?”
公司回覆稱,北京FAB3正積極推動各類不同的MEMS晶圓進入量產階段;公司正積極同時在境內外佈局中試線及量產線。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.